|
Valera Pharmaceuticals makes it easy for patients to take their medicine. Focusing on treatments for urological and endocrine diseases, the company uses its Hydron Technology to develop implants that continuously deliver drugs directly to the bloodstream for a year or more. Its FDA-approved Vantas administers histrelin to patients with prostate cancer. In addition, Valera is developing several drug candidates to treat acromegaly (giantism), bladder disorders, addictive disorders, and other conditions. The company sells its products primarily to urologists in the US. It was acquired by Indevus Pharmaceuticals in 2007.
|
| | | Contact Information | |
Address: |
7 Clarke Dr.
Cranbury, NJ 08512
| | Phone: | 609-409-9010 | | Fax: | 609-409-1650 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2006): | 18.00 M | | Revenue Growth (1 yr): | (-33.00%) | | Employees (2005): | 100 |
|
|
Key People
| | • |
Chairman:
James C. Gale
| | • |
President, CEO, and Director:
David S. Tierney
| | • |
VP Marketing and Commercial Development:
Matthew L. Rue III
|
|
|
